Health Condition 1: H811- Benign paroxysmal vertigo
Conditions
Interventions
Intervention1: Vitamin D: Levels of Vitamin D will be assessed and supplemented when there is deficiency.60000 units of Vitamin D will be given every week till deficiency is overcome.
Control Interve
Sponsors
PES University Institute of Medical Sciences and Research
Eligibility
Inclusion criteria
Inclusion criteria: PATIENTS WITH DIAGNOSIS OF BPPV AND HAVING RESIDUAL DISEASE
Exclusion criteria
Exclusion criteria: Presence of other vestibular disorders. History of significant neurological condition or psychiatric disorders. History of previous spine or ear surgeries. Recent or concurrent use of medications like aminoglycosides, cisplatin and salicylates. Presence of severe uncontrolled comorbidities. Pregnant or breast feeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effectiveness of the following in the treatment of causes of residual dizziness in BPPV in subset of Indian population: A.Betahistine B.Meclizine C.Betahistine + Vitamin D D.Meclizine + Vitamin D At the end the following points will be assessed. Primary endpoints: 1.VSS-SF (Vertigo Symptom Scale - Short Form) Score. 2.Red cell Distribution Width Secondary endpoints: 1.Dizziness Handicap Inventory (DHI). 2.Time to recurrenceTimepoint: Every patient is evaluated at at 0th week, 1st week, 2nd week, 3rd week, 4th week, 6th week, 8th week, 12th week, 16th week, 20th week, 24th week and VSS-sf, DHI score will be recorded. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the health-related quality of life (QOL) before and after the treatment in all four groups.Timepoint: Every patient is evaluated at at 0th week, 1st week, 2nd week, 3rd week, 4th week, 6th week, 8th week, 12th week, 16th week, 20th week, 24th week and VSS-sf, DHI score will be recorded. | — |
Countries
India
Contacts
Public ContactSmitha Chandra B C
PESUIMSR
Outcome results
None listed